Related Experiment Video
Updated: Jun 2, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Current drug therapy for pleural mesothelioma
1Department of Respiratory Medicine, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama, 350-1298, Japan.
Pleural mesothelioma (PM) is a rare cancer linked to asbestos. Current treatments include chemotherapy and immunotherapy, with new combination therapies showing promise for improved survival.
Area of Science:
- Oncology
- Pulmonology
- Toxicology
Background:
- Pleural mesothelioma (PM) is a rare, aggressive malignancy of the pleural lining.
- It typically arises from asbestos exposure, affecting mesothelial cells.
- Median survival is poor, often around one year.
Purpose of the Study:
- To review current systemic treatment options for advanced pleural mesothelioma.
- To explore recent advancements in drug therapy for PM.
- To discuss future therapeutic strategies and novel approaches.
Main Methods:
- Literature review of current systemic therapies for advanced PM.
- Analysis of first-line treatment regimens including chemotherapy and immunotherapy.
- Exploration of emerging treatment paradigms and companion biomarkers.
Main Results:
- First-line options for unresectable PM include cisplatin-pemetrexed and nivolumab-ipilimumab.
- Recent advancements have introduced therapies that significantly improve patient survival.
- Combination immunotherapy and chemotherapy represent promising future directions.
Conclusions:
- Systemic therapy is crucial for advanced PM due to late presentation.
- Novel approaches like chemo-immunotherapy and targeted agents are key for future treatment.
- Tailoring therapies based on histologic and molecular diversity is essential for optimizing outcomes.
More Related Videos
Related Concept Videos
Pleural Disorders: Types and Brief Description
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pneumothorax-II
Clinical Manifestations:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

